Member-Submitted Papers

Advances in Myelofibrosis Management: New Janus Kinase Inhibitors Beyond Ruxolitinib

• Justin Arnall, PharmD, BCOP; Lindsey Lyle, MS, PA-C; and Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP
• Published May 22, 2024, in Journal of the Advanced Practitioner in Oncology

Elranatamab vs. teclistamab: Battle of the BCMA bispecifics in relapsed/refractory multiple myeloma

• Donald C. Moore, Katelynn Granger, Hailey Hill, Allison Karabinos, and James A. Davis
• Published May 11, 2024, in Expert Review of Hematology

Unveiling Discrepant and Rare Dihydropyrimidine Dehydrogenase (DPYD) Results Using an In-House Genotyping Test: A Case Series

• D. Grace Nguyen, PharmD; Sarah A. Morris, PharmD; Annabel Chen; Donald C. Moore, PharmD; Sarah L. Hanson, PharmD; Chris Larck, PharmD; Laura W. Musselwhite, MD; John D. Turner, MD; Mohamed E. Salem, MD; Simeon O. Kwange, MS; Alicia Hamilton, BS; Nury Steuerwald, PhD; and Jai N. Patel, PharmD
• Published May 1, 2024, in Journal of the National Comprehensive Cancer Network

Evaluation of safety outcomes with transitioning obinutuzumab from standard rate to short duration infusion in patients with chronic lymphocytic leukemia

• Caroline Fleck, Allison Karabinos, Allene Cook, Donald C. Moore, and Ryan Jacobs
• Published April 22, 2024, in Leukemia & Lymphoma

PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review

• Donald C. Moore, Joseph B. Elmes, Justin R. Arnall, Scott A. Strassels, and Jai N. Patel
• Published March 10, 2024, in International Immunopharmacology

Pharmacist perspectives on emerging T cell-engaging bispecific therapies in cancer therapeutics

• Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP; Naomi Digiantonio, PharmD, BCPS; Carolyn J. Oxencis, PharmD, BCOP; and Kate D. Taucher, PharmD, MHA, BCOP, FASHP, FAPO
• Published February 23, 2024, in American Journal of Health-System Pharmacy

Alpelisib-Induced Diabetic Ketoacidosis: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System and Review of the Literature

• Julia L. Ziegengeist, Joseph B. Elmes, Scott A. Strassels, Jai N. Patel, and Donald C. Moore
• Published January 12, 2024, in Clinical Breast Cancer

Supporting patients in the transition to the revised pexidartinib dosing regimen: Perspectives from the multidisciplinary clinical and allied health professional team

• Colleen McCabe, Hillary Wright, Kathleen Polson, and Andrew J. Wagner
• Published October 7, 2023, in Orphanet Journal of Rare Diseases

Use of patient-reported outcome measures for oncology drugs receiving accelerated approval

• Donald C. Moore, Joseph B. Elmes, Scott A. Strassels, and Jai N. Patel
• Published September 29, 2023, in Supportive Care in Cancer

The story of the development of generic lenalidomide: How one company thwarted the Hatch-Waxman Act to generate billions of dollars in revenue

• Ryan J. Beechinor, Ghulam Rehman Mohyuddin, David E. Mitchell, Daniel Aaron, and Zahra Mahmoudjafari
• Published September 28, 2023, in Journal of Cancer Policy

Post-Transplant Cyclophosphamide for the Prevention of Graft-vs.-Host Disease in Allogeneic Hematopoietic Cell Transplantation: A Guide to Management for the Advanced Practitioner

• Ekaterina Kachur, Jai N. Patel, Allison L. Morse, Donald C. Moore, and Justin R. Arnall
• Published September 19, 2023, in Journal of the Advanced Practitioner in Oncology

Ocular toxicities associated with antibody drug conjugates and immunotherapy in oncology: clinical presentation, pathogenesis, and management strategies

• Farah Raheem, Nada Alsuhebany, Erin Hickey Zacholski, Nikola Paulic, Anna Sandler, Nathan Uk, and Donald C. Moore
• Published August 30, 2023, in Expert Opinion on Drug Safety

Late-onset cardiotoxicity in patients with HER2-positive metastatic breast cancer receiving trastuzumab-based therapy

• Shuroug A. Alowais, Samantha O. Luk, E. Bridget Kim, Nada Alsuhebany, and Mark Zangardi
• Published August 1, 2023, in Journal of Oncology Pharmacy Practice

A Review of Clinical Data Among Biosimilars: Just How Similar Are They?

• Dennis Marjoncu, PharmD, BCOP
• Published August 2023, in Journal of Hematology Oncology Pharmacy

Safety and efficacy of Vitamin C, Vitamin E, and selenium supplementation in the oncology setting: A systematic review

• AS Barnhart, AL Anthony, KR Conaway, BG Sibbitt, E Delaney, J Haluschak, S Kathula, and AMH Chen
• Published June 15, 2023, in Journal of Oncology Pharmacy Practice

Hepatitis B reactivation in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based therapies: a pharmacovigilance analysis

• Donald C. Moore, Joseph B. Elmes, Justin R. Arnall, Scott A. Strassels, and Jai N. Patel
• Published June 8, 2023, in International Journal of Clinical Pharmacy

Value Assessment of Oncology Pharmacist Interventions

• Mallika P. Patel, PharmD, CPP; Sally Y. Barbour, PharmD, BCOP, CPP, FHOPA; and Meredith T. Moorman, PharmD, BCOP, CPP
• Published May 23, 2023, in Journal of the Advanced Practitioner in Oncology

Outcomes with high dose cytarabine and mitoxantrone induction for adults with mixed phenotype acute leukemia

• Evan Atchley, Taylor M. Weis, Andriy Derkach, Pallavi K. Galera, Wenbin Xiao, Jacob Glass, Susan DeWolf, Mikhail Roshal, Richa Shah, and Sarah E. Stump
• Published May 11, 2023, in Leukemia Research

Ponatinib, asciminib and inotuzumab ozogamicin: A novel drug combination in acute lymphoblastic leukemia

• Jose Tinajero, Paul Koller, and Haris Ali
• Published April 23, 2023, in Leukemia Research

The impact of SARS-CoV2 vaccines on the incidence of graft versus host disease in allogeneic hematopoietic stem cell transplant recipients: a single-center retrospective study

• Dat Ngo, Jason Chen, Jose Tinajero, Ahmed Aribi, Shukaib Arslan, Guido Marcucci, Ryotaro Nakamura, Monzr M. Al Malki, Stephen J. Forman, Sanjeet Dadwal, and Haris Ali
• Published April 18, 2023, in Stem Cell Research & Therapy

Sequencing and combination of current small-molecule inhibitors for chronic lymphocytic leukemia: Where is the evidence?

• Clement Chung, Godsfavour Umoru, Karen Abboud, and Eleanor Hobaugh
• Published April 10, 2023, in European Journal of Haematology

Characterization of a multidisciplinary team's role in hospital discharge for patients receiving hypomethylating agents with venetoclax as induction therapy for acute myeloid leukemia

• Vera Pervitsky, Julie Guglielmo, Benjamin Moskoff, Roxie Kneen, Carol Leija, Deborah Sawicky, Margaret Li Krackeler, Brian A. Jonas, and Ryan Beechinor
• Published March 21, 2023, in Supportive Care in Cancer

Establishing a Workload Productivity Target in an Outpatient Infusion Pharmacy

• Kimberly Haverstick and Mark McMurtrey
• Published March 15, 2023, in American Journal of Management

Updates in the Treatment of Non-Metastatic Castrate-Resistant Prostate Cancer: The Benefit of Second-Generation Androgen Receptor Antagonists

• Matthew J. Hadfield, DO; Vikram Lyall, MD; Lisa M. Holle, PharmD, BCOP; and Morgan Dennison
• Published February 24, 2023, in Annals of Pharmacotherapy

A Case of Heavily Pretreated HER2+ Colorectal Liver Metastases Responsive to Hepatic Arterial Infusion Chemotherapy

• Ryan J. Beechinor, Mustafa F. Abidalhassan, Deborah F. Small, Huong K. Hoang, Ramit Lamba, Thomas W. Loehfelm, Cameron C. Foster, Michael Z. Koontz, Edward Jae-Hoon Kim, Mary Cho, and Sepideh Gholami
• Published February 23, 2023, in Clinical Colorectal Cancer and Other Gastrointestinal Malignancies

Expansion of MyDispense: A Descriptive Report of Simulation Activities and Assessment in a Certified Pharmacy Technician Training Program

• Cassandra R. Doyno, Lisa M. Holle, Renee Puente, Sharee Parker, Lauren M. Caldas, and Barbara Exum
• Published February 16, 2023, in Pharmacy

Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management

• Melissa Sandley and Jonathan Angus
• Published February 13, 2023, in Leukemia & Lymphoma

Concomitant Venetoclax and Imatinib for Comanaging Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia: A Case Report

• Eugene R. Przespolewski, PharmD; Jeffrey Baron, PharmD; Farshid Kashef, MD, MBS; Kai Fu, MD, PhD; Sheila N. Jani Sait, PhD; Francisco Hernandez-Ilizaliturri, MD; and James Thompson, MD, MS
• Published February 2023, in Journal of the National Comprehensive Cancer Network

Dosing of 3 Targeted Agents in Novel Drug Combinations Used at the Precision Medicine Clinic of the University of California San Diego

• Mina Nikanjam, MD, PhD; Jose Tinajero, PharmD; Mary McGann, PharmD, BCOP; Jerry Li, PharmD; Jincheng Yang, PharmD; Felicity Shen, PharmD; Jason K. Sicklick, MD; Shumei Kato, MD; Edmund Capparelli, PharmD; and Razelle Kurzrock, MD
• Published February 2023, in Journal of Hematology Oncology Pharmacy

Does Palbociclib Need to Be Interrupted for Concurrent Radiotherapy?

• Ryan Beechinor, PharmD, BCPS, BCOP
• Published December 19, 2022, in Oncology Connection

Sutimlimab: A Complement C1s Inhibitor for the Management of Cold Agglutinin Disease-Associated Hemolysis

• Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP, and Justin R. Arnall, PharmD, BCOP
• Published December 8, 2022, in Annals of Pharmacotherapy

Platelet recovery with ibrutinib therapy in patient with treatment-refractory immune thrombocytopenia

• Paul Christopher Parish, Donald C. Moore, Justin Arnall, Teresa J. Howell, Brittany Dick, and Richard Cambareri
• Published November 28, 2022, in Annals of Hematology

Real-world experience and considerations on concomitant caplacizumab and anticoagulation in thrombotic thrombocytopenic purpura

• Benson Meek, Nuti Desai, Donald C. Moore, Thuy Tran, Mary Ann Knovich, and Justin Arnall
• Published November 28, 2022, in Annals of Hematology

All Hands on Deck: An Interdisciplinary Approach is Critical to Support Adherence of Oral Anticancer Medications

• Vera Pervitsky, PharmD, and Ryan Beechinor, PharmD, BCPS, BCOP
• Published October 30, 2022, in Oncolytics Today

Safety and Efficacy of Intravenous Bisphosphonates for the Treatment of Hypercalcemia in Patients with Cancer and Baseline Renal Dysfunction

• Emily H. Hsu, PharmD, and Ryan Beechinor, PharmD, BCPS, BCOP
• Published August 2022, in Journal of Hematology Oncology Pharmacy

Evaluation of Pharmacist Impact on Patients Initiating Eculizumab for Atypical Hemolytic Uremic Syndrome in the Inpatient Setting

• Paul Christopher Parish, PharmD; Donald C. Moore, PharmD, BCPS, BCOP, DLPA; Megan Wayman, PharmD; and Justin Arnall, PharmD, BCOP
• Published July 29, 2022, in Annals of Pharmacotherapy

Optimizing Multidisciplinary Treatment-Related Adverse Effects Detection and Reduction in Patients Undergoing Active Cancer Treatments in Ambulatory Infusion Centers

• Clement Chung, PharmD, MS; Alison Rome, MD; Monica Desai, MD; Fred Abanonu, MD; and Cesar De la Casas, MD, MPH
• Published July 1, 2022, in JCO Oncology Practice

Tafasitamab and lenalidomide for relapsed/refractory diffuse large B-cell lymphoma in a patient on chronic intermittent hemodialysis

• Donald C. Moore, Keren A. Eagers, Amanda Janes, and Mauricio Pineda-Roman
• Published May 18, 2022, in Journal of Oncology Pharmacy Practice

Perceptions of a virtual interview process for pharmacy residents during the COVID-19 pandemic: A multisite survey of residency candidates, preceptors, and residency program directors

• Ryan J. Beechinor, PharmD, BCPS, BCOP; Ifeoma Mary Eche, PharmD, BCPS, BCCP, CACP; Nicholas Edmonds, PharmD, BCPS; Jason Mordino, PharmD, BCCCP; Hope Serafin, PharmD, BCPS; Lauren Roller, PharmD, BCCCP; Tasleem Spracklin, PharmD, BCPS; Genevieve Hayes, PharmD, MSPharm, BCPS; Aaron Hamby, PharmD; Krutika N. Mediwala, PharmD, BCPS, BCIDP; Drew L. Armstrong, PharmD, BCACP, AAHIVP; Maegan L. Rogers, PharmD, BCPS, CDE; Mark A. Baje, PharmD, BCCCP; Helen S. Lee, PharmD, BCPS AQ-ID; Kelly C. Lee, PharmD, MAS, BCPP; Marcie Lepkowsky, PharmD, BCGP; Fanny Li, PharmD, BCPS, BCCP; Mandy Morris, PharmD, BCPS, BCCP; Rita Jue Quan, PharmD, BCPS; Christopher Yamamoto, PharmD, BCPS; Kirsten H. Ohler, PharmD, BCPS, BCPPS; Mike D. Kraft, PharmD, BCNSP; Kate Starosta, PharmD, BCPS; Tricia Parker, PharmD, BCPS; and Patricia Poole, PharmD, BCPS AQ-ID, BCACP
• Published May 8, 2022, in American Journal of Health-System Pharmacy

Climate change is here: What will the profession of pharmacy do about it?

• Ryan J. Beechinor, PharmD, BCPS, BCOP; Adam Overberg, PharmD, BCPS, DABAT; Caitlin S. Brown, PharmD, BCCCP; Sarah Cummins, PharmD; and Jason Mordino, PharmD, BCCCP
• Published May 4, 2022, in American Journal of Health-System Pharmacy

Impact of body mass index (BMI) on the efficacy of plerixafor for hematopoietic progenitor cell (HPC) mobilization

• Spencer K. Yingling, Rebecca M. Gonzalez, Megan Dillaman, Kelsea Seago, Sijin Wen, Kelly G. Ross, Lauren Veltri, and Aaron Cumpston
• Published April 25, 2022, in Bone Marrow Transplantation